Various approaches targeting the cytokine to the tumor, such as colloidal gold-bound TNF-α [272], gene transfer [273], recombinant TNF-α fused to an antibody anti-fibronectin of tumor endothelium (L19-TNF) [274], failed to reach significant results in clinical trials. Here, FN1 is linked to neoplasm.